Effect of FDG-PET/CT for Simulation and Radiation Treatment Planning in Oral Cancer Patients

Phrase II Single Arm Study of Effect of FDG-PET/CT for Simulation and Radiation Treatment Planning in Oral

Status

UNKNOWN

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03008694

Enrollment

100

Registered

2017-01-02

Start date

2017-01-31

Completion date

2019-01-31

Last updated

2017-01-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oral Cancer, Radiotherapy; Complications

Keywords

PET/CT

Brief summary

This study evaluates the effect of FDG-PET/CT for Simulation and Radiation Treatment Planning in oral Cancer patients. Progress-free survival (PFS) will be compared with historical control as defined in the protocol

Detailed description

Radiotherapy improves local control and overall survival for oral cavity cancer patients after surgery. However, limited locoregional control remains a key issue in the management of oral cavity carcinomas. Appropriate target selection is a key issue in the radiotherapy of oral cavity cancer. The purpose of this study is to determine the locoregional control in PET/CT based radiotherapy treatment planning in the treatment of oral cancer

Interventions

DEVICEPET/CT

pet/ct is used as radiotherapy simulation

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Histologically confirmed oral squamous-cell carcinoma * Age \> 17 years * Signed informed consent * ECOG Performance status 0-2 * Must be able to start RT within 4 weeks after PET/CT simulation

Exclusion criteria

* stage IV disease diagnosed before acquisition of staging PET/CT * prior radiotherapy to oral and neck * Unable to understand study participation * Claustrophobia * pregnant or breast feeding mothers

Design outcomes

Primary

Measure	Time frame
progress free survival	baseline to 2 years

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026